Latest breakthroughs in cancer research, treatment, and prevention
606 artigos
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
A phase 1 trial of a neoantigen DNA vaccine for glioblastoma found strong immune responses and survival rates exceeding historical benchmarks.
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
A phase 3 trial finds nivolumab-based regimens offer no survival advantage over durvalumab for unresectable stage III NSCLC.
A newly identified enzyme links lactate metabolism to liver cancer progression, and a natural compound delivered via nanoparticles shows striking anti-tumor results.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
The FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma, a rare and aggressive bile duct cancer with limited treatment options.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
A large retrospective study tests whether AI-enhanced ECGs can flag cardiac risk before chemotherapy, potentially protecting cancer patients from heart damage.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
